Bergmann Jacob Siewertsen, Hamm Sebastian Rask, Bering Louise, Pedersen Christian Ross, Bock Ask, Heidari Safura-Luise, Villadsen Gerda Elisabeth, Fialla Annette Dam, Willemoe Gro Linno, Holland-Fischer Peter, Nielsen Susanne Dam
Viro-Immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Department of Surgical Gastroenterology and Transplantation, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
NPJ Vaccines. 2025 Aug 2;10(1):181. doi: 10.1038/s41541-025-01233-7.
Liver transplant (LTx) recipients risk severe COVID-19. Vaccination reduces this risk. However, there may be side effects, including elevated alanine transaminase (ALT) which could lead to increased use of liver biopsy. We aimed to describe prevalence and relative incidence of elevated ALT 90 days before and after BNT162b2 vaccination in LTx recipients. Furthermore, we aimed to describe changes in prevalence of liver biopsies before and after BNT162b2 vaccination. We included 393 LTx recipients from The Danish Comorbidity in Liver Transplant Recipients (DACOLT) study. We calculated prevalence of elevated ALT and liver biopsies before and after each BNT162b2 vaccine dose. We used self-control case series (SCCS) analysis to investigate whether vaccination was associated with higher relative incidence of elevated ALT. Prevalence of elevated ALT, around each vaccine dose, was comparable. We did not find higher relative incidence of elevated ALT after vaccination. The prevalence of liver biopsies around vaccination was comparable.
肝移植（LTx）受者面临严重新型冠状病毒肺炎（COVID-19）的风险。接种疫苗可降低这种风险。然而，可能会有副作用，包括丙氨酸转氨酶（ALT）升高，这可能导致肝活检的使用增加。我们旨在描述LTx受者接种BNT162b2疫苗前后90天ALT升高的患病率和相对发病率。此外，我们旨在描述BNT162b2疫苗接种前后肝活检患病率的变化。我们纳入了来自丹麦肝移植受者合并症（DACOLT）研究的393名LTx受者。我们计算了每剂BNT162b2疫苗接种前后ALT升高和肝活检的患病率。我们使用自我对照病例系列（SCCS）分析来调查接种疫苗是否与ALT升高的相对较高发病率相关。每次疫苗接种前后ALT升高的患病率相当。我们没有发现接种疫苗后ALT升高的相对较高发病率。接种疫苗前后肝活检的患病率相当。
